Sunomix Therapeutics is a privately held biopharmaceutical company pioneering the development of proprietary mRNA-LPN technology, Antibody Drug Conjugates Nanoparticules for the treatment of cancers and infectious diseases. Sunomix Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent drugs to selectively kill cancer cells. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

The Company combines all building blocks of individualized immunotherapies under one roof.

Sunomix Therapeutics cutting-edge technologies range from individualized nanoparticules, virus-like particles (VLPs), mRNA-LPN, genetic vectors through innovative proteomic array biomarkers and therapeutic antibody used to grow a diverse infectious diseases, cancer treatment and prevention portfolio.

We also develops new ways of vaccine delivery for effective and safe immunization. Our experimental vaccines include vaccines against pandemic influenza, Herpes, HIV, and other emerging, biodefense-relevant infectious diseases and cancer .

Sunomix Therapeutics’s approach is validated by top-tier corporate and universities partnerships.

Sunomix Therapeutics has been awarded several grants from the National Institutes of Health (NIH) and CDC to advance the mRNA-LPN vaccine platform.

Project Number: 1R41AI138764-01